Industry Report Cites Cost Savings Of Drug-Resistant Infection Screening
This article was originally published in The Gray Sheet
Executive Summary
More frequent testing of patients for drug-resistant infections could improve health outcomes and save billions of dollars, according to a new study sponsored by the device industry
You may also be interested in...
Universal Screening For MRSA Does Not Reduce Infections – JAMA Study
Using a rapid molecular assay to screen all surgical patients on admission for a prevalent drug-resistant infection did not reduce the incidence of hospital-acquired infections in a Swiss study involving more than 20,000 patients
Universal Screening For MRSA Does Not Reduce Infections – JAMA Study
Using a rapid molecular assay to screen all surgical patients on admission for a prevalent drug-resistant infection did not reduce the incidence of hospital-acquired infections in a Swiss study involving more than 20,000 patients
Market For Complex Genetic Tests Expands Beyond Specialized Labs
The market for sophisticated gene tests has the potential to greatly expand with the introduction of new "push-button" systems that require less expertise to operate